Protective Effect of Rivaroxaban Against Amyloid Pathology and Neuroinflammation Through Inhibiting PAR-1 and PAR-2 in Alzheimer's Disease Mice.
J Alzheimers Dis
; 86(1): 111-123, 2022.
Article
in En
| MEDLINE
| ID: mdl-35001892
ABSTRACT
BACKGROUND:
Recent studies have revealed that atrial fibrillation (AF) patients have a high risk of developing cognitive impairment, vascular dementia, and Alzheimer's disease (AD). Some reports suggest that the application of oral anticoagulant with an appropriate dose may have a preventive effect on AD. However, which oral anticoagulant drug is more appropriate for preventing AD and the underlying mechanism(s) is still unknown.OBJECTIVE:
The aim of the present study was to assess the treatment effect of rivaroxaban administration as well as investigate the roles of PAR-1 and PAR-2 in the ADâ+âCAA mice model.METHODS:
In the present study, we compared a traditional oral anticoagulant, warfarin, and a direct oral anticoagulant (DOAC), rivaroxaban, via long-term administration to an AD with cerebral amyloid angiopathy (CAA) mice model.RESULTS:
Rivaroxaban treatment attenuated neuroinflammation, blood-brain barrier dysfunction, memory deficits, and amyloid-ß deposition through PAR-1/PAR-2 inhibition in the ADâ+âCAA mice model compared with warfarin and no-treatment groups.CONCLUSION:
The present study demonstrates that rivaroxaban can attenuate AD progress and can be a potential choice to prevent AD.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Cerebral Amyloid Angiopathy
/
Alzheimer Disease
Limits:
Animals
/
Humans
Language:
En
Journal:
J Alzheimers Dis
Journal subject:
GERIATRIA
/
NEUROLOGIA
Year:
2022
Document type:
Article
Affiliation country: